Deuteration versus ethylation – strategies to improve the metabolic fate of an 18F-labeled celecoxib derivative-Reference-Cited by-同舟云学术

Deuteration versus ethylation – strategies to improve the metabolic fate of an 18F-labeled celecoxib derivative

Published:2020 Issue:63 Volume:10 Page:38601-38611
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Laube Markus¹²³⁴^ORCID,Gassner Cemena¹²³⁴⁵,Neuber Christin¹²³⁴^ORCID,Wodtke Robert¹²³⁴^ORCID,Ullrich Martin¹²³⁴^ORCID,Haase-Kohn Cathleen¹²³⁴^ORCID,Löser Reik¹²³⁴^ORCID,Köckerling Martin⁶⁷⁸⁹⁴^ORCID,Kopka Klaus¹²³⁴^ORCID,Kniess Torsten¹²³⁴^ORCID,Hey-Hawkins Evamarie¹⁰¹¹¹²¹³⁴^ORCID,Pietzsch Jens¹²³⁴⁵^ORCID

Affiliation:

1. Helmholtz-Zentrum Dresden-Rossendorf

2. Institute of Radiopharmaceutical Cancer Research

3. 01328 Dresden

4. Germany

5. Faculty of Chemistry and Food Chemistry

6. University of Rostock

7. Institute of Chemistry

8. Department of Inorganic Solid State Chemistry

9. D-18059 Rostock

10. Leipzig University

11. Faculty of Chemistry and Mineralogy

12. Institute of Inorganic Chemistry

13. D-04103 Leipzig

Abstract

The aim of this study is to investigate the influence of deuteration and elongation on an ¹⁸F-labeled COX-2 inhibitor with focus on metabolic stability to develop suitable COX-2 targeting radiotracers.

Funder

Deutsche Forschungsgemeinschaft

Helmholtz Association

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2020/RA/D0RA04494F

Reference61 articles.

1. The COXIB Experience: A Look in the Rearview Mirror

2. Structure–activity relationships for the synthesis of selective cyclooxygenase 2 inhibitors: an overview (2009–2016)